University of Pennsylvania investigators and Children’s Hospital of Philadelphia clinicians reported meaningful clinical benefits after an mRNA-based CRISPR base-editing treatment for an infant with CPS1 deficiency, while emphasizing the intervention was not a trial. Lead investigators Kiran Musunuru and Rebecca Ahrens-Nicklas framed the case as expanded access clinical care rather than a scientifically powered study. In statements highlighted around the patient’s progress—including ability to eat a normal protein-filled diet—Musunuru argued that the regulatory and evidentiary framework must keep pace with fast-moving genome editing capabilities. The comments place the case within a broader competition among base-editing developers pushing toward clinical trial programs. For the sector, the messaging underscores how regulators may evaluate safety and efficacy evidence differently for single-patient expanded access experiences versus formal clinical trials, even when outcomes appear promising.